EPiQ Market Intelligence Program: Pancreatic Cancer

EPiQ Market Intelligence Program: Pancreatic Cancer published by WWMR, Inc.. This annual information service price starts from US $ 17500.

Introduction

Abstract

The first and only pancreatic cancer market intelligence program to be based on the review of over 500 longitudinal patient charts.

• Longitudinal patient and physician tracking over 3 years
• Actual clinical activity captured from patient charts, not physician recall
• Patient segmentation by type of pancreatic cancer and line of drug therapy

WWMR expert analysis includes:

• Qualitative analysis of nearly 100 current and future drug treatments
• Thought leader opinions on key unmet medical needs and clinical potential for new mechanisms of action
• Comprehensive review of clinical literature and industry developments

Program Features:

• Monthly drug treatment data by type of pancreatic cancer (exocrine and endocrine) and line of therapy, January 2001 to January 2004
• Semi-annual data updates through June 2005
• Drug-treated patient forecasts by patient segment - endocrine and exocrine patients by stage, through 2013
• Market forecasts by drug class, through 2013
• Product-by-product evaluations of investigational agents
• Incidence, prevalence, and mortality forecasts, through 2013
• Quantitative treatment trend analysis
• Unmet needs analysis
• Disease and current treatment review

Program Benefits:

• Pinpoint the specific patient segments that have high market potential in the next 10 years
• Compare the epidemiology, current treatment patterns, patient demographics, and drug-treated population forecasts by patient segment
• Target specific patient segments that will benefit most from drugs in the pipeline
• Anticipate upcoming competitors and product licensing opportunities
• Recognize the impact of unique market dynamics - including the potential off-label usage - on product uptake forecasts
• Develop patient segment-specific and drug class-specific forecasts for the overall market and for key patient segments
• Understand the characteristics of patients unmet need

Program Deliverables:

• Fully-referenced color report
• Comprehensive interactive appendix
• Semi-annual data updates

Table of Contents

• I. EXECUTIVE SUMMARY.......................................................................................................1
• II. Introduction and Methodology.............................................................................................1
  • A. Background................................................................................................................2
  • B. Objectives of EPiQ Pancreatic Cancer Market Intelligence Program...................................3
  • C. Methodology..............................................................................................................4
  • D. Definitions..................................................................................................................6
• III. Disease Definition and Staging............................................................................................7
  • A. Exocrine Pancreatic Cancer..........................................................................................8
    • 1. Etiology and risk factors........................................................................................9
    • 2. Symptoms and pathology......................................................................................9
    • 3. Diagnosis............................................................................................................10
    • 4. Staging.............................................................................................................13
    • 5. Prognosis..........................................................................................................14
  • B. Endocrine Pancreatic Cancer......................................................................................15
    • 1. Etiology and risk factors......................................................................................15
    • 2. Symptoms and Pathology......................................................................................15
    • 3. Diagnosis and Staging..........................................................................................17
    • 4. Prognosis............................................................................................................18
  • C. References...................................................................................................................19
• IV. Epidemiology...................................................................................................................20
  • A. Incidence.................................................................................................................22
  • B. Prevalence................................................................................................................25
  • C. Mortality..................................................................................................................28
  • D. Drug-Treated Populations............................................................................................31
    • 1. Drug-Treated Patients by Type of Cancer and Stage, 2003.....................................32
    • 2. Drug-Treated Patients by Line of Therapy -- Overall and by Type of Cancer, 2003.....32
    • 3. Drug-Treated Population Forecast, 2003-2013......................................................36
  • E. Patient Demographics................................................................................................39
    • 1. Gender.............................................................................................................39
    • 2. Age 39
    • 3. Body Surface Area.............................................................................................39
    • 4. Physician Practice Setting.......................................................................................40
    • F. References................................................................................................................44
• V. Current Treatment.............................................................................................................45
  • A. Standards of Care.....................................................................................................46
    • 1. Surgical options....................................................................................................46
    • 2. Radiation therapy.................................................................................................48
    • 3. Chemotherapy...................................................................................................48
  • B. Top Drug Regimens -- By Cancer Type.........................................................................51
    • 1. All pancreatic cancer -- top drug regimens............................................................51
    • 2. Exocrine pancreatic cancer -- top drug regimens....................................................52
    • 3. Endocrine pancreatic cancer -- top drug regimens..................................................53
  • C. Top Drug Regimens -- By Line of Therapy......................................................................55
    • 1. First-line drug regimens..........................................................................................55
    • 2. Second-line drug regimens.....................................................................................55
  • D. Top Agents -- By Stage and Line of Therapy..................................................................59
    • 1. Exocrine pancreatic cancer.................................................................................59
    • 2. Endocrine pancreatic cancer...............................................................................63
  • E. Trends in Monthly Share for Top Agents.......................................................................64
  • F. Additional Features of Pancreatic Cancer........................................................................65
    • 1. Annual cost of top agents...................................................................................65
    • 2. Lines of therapy per patient................................................................................65
    • 3. Average Length of Therapy.................................................................................66
  • G. References................................................................................................................68
• VI. UNMET NEEDS................................................................................................................69
  • A. Improved Diagnostics, Sub-Typing, and Monitoring.......................................................70
    • 1. Screening and diagnosis....................................................................................70
    • 2. Determining course of therapy and monitoring......................................................70
    • B. Effective, Low-Toxicity Anti-Cancer Drug Treatments.......................................................72
    • C. Improved Understanding of Molecular Pathology..........................................................73
    • D. Better Supportive Care...............................................................................................74
    • E. Improved Clinical Trial Design....................................................................................75
      • 1. Large, randomized trials with homogeneous populations...........................................75
      • 2. Careful endpoint selection...................................................................................75
    • F. References................................................................................................................76
• VII. Pipeline Development........................................................................................................77
  • A. Technical Assessment.................................................................................................78
    • 1. Immunotherapies................................................................................................78
    • 2. Vascular endothelial growth factor (VEGF) antagonists...........................................79
    • 3. Epidermal growth factor receptor (EGFR) inhibitors................................................80
    • 4. Platinum analogs...............................................................................................81
    • 5. Taxanes (anti-microtubule agents).........................................................................81
    • 6. COX-2 inhibitors................................................................................................81
    • 7. Farnesyl transferase inhibitors..............................................................................82
    • 8. Metalloproteinase inhibitors................................................................................82
    • 9. DNA topoisomerase I inhibitors...........................................................................82
  • B. Commercial Evaluation..............................................................................................83
    • 1. Preregistered agents...........................................................................................83
    • 2. Phase III agents..................................................................................................85
    • 3. Phase II.............................................................................................................89
    • 4. Phase I.............................................................................................................99
  • C. References..............................................................................................................104
• VIII. Current and Future Market Projections...............................................................................105
  • A. Total Pancreatic Cancer Market Forecast, Methodology, and Assumptions.....................105
  • B. Exocrine Pancreatic Cancer -- Market Forecast, by Drug Class and by Line of Therapy and Drug Class.............................................................................................................112
    • 1. Exocrine pancreatic cancer, all lines of drug therapy...........................................112
    • 2. Exocrine pancreatic cancer, first-line drug therapy...............................................114
    • 3. Exocrine pancreatic cancer, second-line drug therapy..........................................116
    • 4. Exocrine pancreatic cancer third-plus-line drug therapy.........................................117
  • C. Endocrine Pancreatic Cancer -- Market Forecast, by Drug Class....................................119
  • D. References..............................................................................................................121

LIST OF FIGURES

• Figure IV-1: Pancreatic Cancer Epidemiology Forecast.................................................................21
• Figure IV-2: Pancreatic Cancer Incidence Forecast......................................................................23
• Figure IV-3: Historical Incidence of Pancreatic Cancer.................................................................23
• Figure IV-4: Pancreatic Cancer Prevalence Forecast.....................................................................26
• Figure IV-5: Historical Prevalence of Pancreatic Cancer...............................................................26
• Figure IV-6: Pancreatic Cancer Mortality Forecast.......................................................................29
• Figure IV-7: Historical Mortality of Pancreatic Cancer..................................................................29
• Figure IV-8: Number of Exocrine Pancreatic Cancer Patients By Line of Therapy.............................34
• Figure IV-9: Number of Endocrine Pancreatic Cancer Patients By Line of Therapy...........................35
• Figure IV-10: Drug-Treated Pancreatic Cancer Population Forecast................................................37
• Figure IV-11: Pancreatic Cancer Drug-Treated Population Forecast, by Type and Line of Therapy......38
• Figure IV-12: Patients by Physician Practice Setting, 2003............................................................42
• Figure IV-13: Physicians by Practice Setting, 2003......................................................................43
• Figure V-1: Top Regimens Used to Treat Pancreatic Cancer, 2003................................................52
• Figure V-2: Top Regimens Used to Treat Exocrine Pancreatic Cancer, 2003...................................53
• Figure V-3: Top Regimens Used to Treat Endocrine Pancreatic Cancer, 2003.................................53
• Figure V-4: Pancreatic Cancer Treatment Tree.............................................................................58
• Figure V-5: Longitudinal Comparison of Top Regimens Across Lines of Therapy for Exocrine Pancreatic Cancer, 2003.................................................................................................................59
• Figure V-6: Monthly Share for Top Drugs in First-Line Therapy, Stage III/IV, Exocrine Pancreatic Cancer64
• Figure V-7: Lines of Therapy Received Per Patient........................................................................66
• Figure V-8: Average Length of Drug Regimen (Exocrine Pancreatic Cancer), 2003..........................67
• Figure VIII-1: Pancreatic Cancer Drug Market Forecast, by Drug/Drug Class, 2013.....................107
• Figure VIII-2: Pancreatic Cancer Drug Market Forecast, by Patient Segment, 2003-2013..............107

LIST OF TABLES

• Table II-1: General Summary of Considerations in Market Forecast
• Table III-1: Diagnostic Methods for Pancreatic Cancer
• Table III-2: AJCC Classification for Pancreatic Cancer
• Table III-3: Endocrine Tumors of the Pancreas
• Table IV-1: Drug-Treated Population by Type and Stage of Pancreatic Cancer, 2003
• Table IV-2: Drug-Treated Population by Patient Body Surface Area, 2003
• Table V-1: Annual Cost of Top Agents Used to Treat Pancreatic Cancer, 2003
• Table VII-1: Summary by Phase of Drugs in Clinical Development for Pancreatic Cancer, 2004
• Table VII-2: Drugs in Phase III, Preregistration, or Registration for Pancreatic Cancer Worldwide, 2004
• Table VII-3: Launched Drugs in US Phase II Clinical Trials for Pancreatic Cancer, 2004
• Table VII-4: Pipeline Drugs in US Phase II Clinical Trials for Pancreatic Cancer, 2004 -- Part 1 of 3
• Table VII-5: Pipeline Drugs in US Phase II Clinical Trials for Pancreatic Cancer, 2004 -- Part 2 of 3
• Table VII-6: Pipeline Drugs in US Phase II Clinical Trials for Pancreatic Cancer, 2004 -- Part 3 of 3
• Table VII-7: Pipeline Drugs in US Phase II Clinical Trials for Pancreatic Cancer, 2004 -- Part 1 of 3
• Table VII-8: Drugs in Ex-US Phase II Clinical Trials for Pancreatic Cancer, 2004
• Table VII-9: Launched Drugs in US Phase I Clinical Trials for Pancreatic Cancer, 2004
• Table VII-10: Pipeline Drugs in US Phase I Clinical Trials for Pancreatic Cancer, 2004 -- Part 1 of 2
• Table VII-11: Pipeline Drugs in US Phase I Clinical Trials for Pancreatic Cancer, 2004 -- Part 2 of 2
• Table VII-12: Drugs in Ex-US Phase I Clinical Trials for Pancreatic Cancer, 2004
• Table VIII-1: Assumptions Regarding Clinical Eligibility and Treatment Rates, by Patient Segment, 2008-2013
• Table VIII-2: Total Pancreatic Cancer Drug Treatment Market Forecast, by Drug/Drug Class, 2003-2013
• Table VIII-3: Exocrine Pancreatic Cancer Drug Treatment (All Lines of Therapy) Market Forecast, by Drug/Drug Class, 2003-2013
• Table VIII-4: Exocrine Pancreatic Cancer First-Line Drug Treatment Market Forecast, by Drug/Drug Class, 2003-2013
• Table VIII-5: Exocrine Pancreatic Cancer Second-Line Drug Treatment Market Forecast, by Drug/Drug Class, 2003-2013
• Table VIII-3: Exocrine Pancreatic Cancer Third-Plus-t-Line Drug Treatment Market Forecast, by Drug/Drug Class, 2003-2013
• Table VIII-3: Endocrine Pancreatic Cancer Drug Treatment (All Lines of Therapy) Market Forecast, by Drug/Drug Class, 2003-2013

Related Reports